212 related articles for article (PubMed ID: 10995600)
1. Comparative in vivo effects of irbesartan and losartan on angiotensin II receptor binding in the rat kidney following oral administration.
Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
Clin Sci (Lond); 2000 Oct; 99(4):331-41. PubMed ID: 10995600
[TBL] [Abstract][Full Text] [Related]
2. In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan.
Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
Am J Hypertens; 2000 Sep; 13(9):1005-13. PubMed ID: 10981551
[TBL] [Abstract][Full Text] [Related]
3. Sympatho-inhibitory properties of various AT1 receptor antagonists.
Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
J Hypertens Suppl; 2002 Jun; 20(5):S3-11. PubMed ID: 12184061
[TBL] [Abstract][Full Text] [Related]
4. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay.
Belz GG; Butzer R; Kober S; Mang C; Mutschler E
Clin Pharmacol Ther; 1999 Oct; 66(4):367-73. PubMed ID: 10546920
[TBL] [Abstract][Full Text] [Related]
5. Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport.
Hatch M; Freel RW; Shahinfar S; Vaziri ND
J Pharmacol Exp Ther; 1996 Jan; 276(1):187-93. PubMed ID: 8558429
[TBL] [Abstract][Full Text] [Related]
6. Tonic suppression of spontaneous baroreceptor reflex by endogenous angiotensins via AT(2) subtype receptors at nucleus reticularis ventrolateralis in the rat.
Lin K; Chan SH; Chan JY
Synapse; 2001 Apr; 40(1):85-94. PubMed ID: 11170225
[TBL] [Abstract][Full Text] [Related]
7. Characterization of angiotensin II antagonism displayed by Ib, a novel nonpeptide angiotensin AT(1) receptor antagonist.
Wu J; Wang Q; Guo J; Hu Z; Yin Z; Xu J; Wu X
Eur J Pharmacol; 2008 Jul; 589(1-3):220-4. PubMed ID: 18571160
[TBL] [Abstract][Full Text] [Related]
8. Characterization and function of the bovine kidney epithelial angiotensin receptor subtype 4 using angiotensin IV and divalinal angiotensin IV as receptor ligands.
Handa RK; Harding JW; Simasko SM
J Pharmacol Exp Ther; 1999 Dec; 291(3):1242-9. PubMed ID: 10565848
[TBL] [Abstract][Full Text] [Related]
9. The comparative pharmacology of angiotensin II receptor antagonists.
Burnier M; Maillard M
Blood Press Suppl; 2001; 1():6-11. PubMed ID: 11333013
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Angiotensin II receptors during pregnancy induces malformations in developing rat kidney.
Sánchez SI; Seltzer AM; Fuentes LB; Forneris ML; Ciuffo GM
Eur J Pharmacol; 2008 Jun; 588(1):114-23. PubMed ID: 18495111
[TBL] [Abstract][Full Text] [Related]
11. AT(1)-receptor blockers: differences that matter.
Gradman AH
J Hum Hypertens; 2002 Aug; 16 Suppl 3():S9-S16. PubMed ID: 12140723
[TBL] [Abstract][Full Text] [Related]
12. Hypotensive effect of angiotensin II after AT1-receptor blockade with losartan.
Matys T; Pawlak R; Kucharewicz I; Chabielska E; Buczko W
J Physiol Pharmacol; 2000 Mar; 51(1):161-6. PubMed ID: 10768859
[TBL] [Abstract][Full Text] [Related]
13. The angiotensin AT(1) receptor antagonist irbesartan has near-peptide affinity and potently blocks receptor signaling.
Hines J; Fluharty SJ; Sakai RR
Eur J Pharmacol; 1999 Nov; 384(1):81-9. PubMed ID: 10611423
[TBL] [Abstract][Full Text] [Related]
14. Chronic angiotensin II antagonism with losartan in one-kidney, one clip hypertensive rats: effect on cardiac hypertrophy, urinary sodium and water excretion and the natriuretic system.
Garcia R; Bonhomme MC; Diebold S
J Hypertens; 1996 Jan; 14(1):81-9. PubMed ID: 12013499
[TBL] [Abstract][Full Text] [Related]
15. Renal AT1 receptor: autoradiographic localization and quantification in rat.
Asano N; Ogura T; Mimura Y; Kishida M; Kataoka H; Otsuka F; Yamauchi T; Makino H
Res Commun Mol Pathol Pharmacol; 1998 May; 100(2):161-70. PubMed ID: 9667070
[TBL] [Abstract][Full Text] [Related]
16. Decreased binding sites of angiotensin II in rat LY-80 and AH109A tumour and human gastric cancer using quantitative in vitro autoradiography.
Kohzuki M; Tanda S; Hori K; Suzuki M; Yoshida K; Sato T
Int Angiol; 2000 Mar; 19(1):52-8. PubMed ID: 10853686
[TBL] [Abstract][Full Text] [Related]
17. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats.
Culman J; von Heyer C; Piepenburg B; Rascher W; Unger T
Eur J Pharmacol; 1999 Feb; 367(2-3):255-65. PubMed ID: 10079000
[TBL] [Abstract][Full Text] [Related]
18. DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan.
Goldberg MR; Lo MW; Christ DD; Chiou R; Furtek CI; Amit O; Carides A; Biollaz J; Piguet V; Nussberger J; Brunner HR
Clin Pharmacol Ther; 1997 Jan; 61(1):59-69. PubMed ID: 9024174
[TBL] [Abstract][Full Text] [Related]
19. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.
Vanderheyden PM; Fierens FL; De Backer JP; Fraeyman N; Vauquelin G
Br J Pharmacol; 1999 Feb; 126(4):1057-65. PubMed ID: 10193788
[TBL] [Abstract][Full Text] [Related]
20. In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency.
Beauchamp HT; Chang RS; Siegl PK; Gibson RE
J Pharmacol Exp Ther; 1995 Feb; 272(2):612-8. PubMed ID: 7853174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
